CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels

NCT03731169 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Aspergillosis Invasive
Fungal Infection

Interventions

GENETIC: Voriconazole genotype-specific dosing
DRUG: Standard of Care

Sponsor

University Health Network, Toronto